Lack of association between CDKN2A germline mutations and survival in patients with melanoma: A retrospective cohort study

Note: Funding Information: IRB approval status: Ethical approval was granted by the ethical review boards of PALGA, Houten, the Netherlands, and Leiden University Medical Center (protocol number, P00.117).All adults newly diagnosed with invasive, clinically localized, primary cutaneous melanoma between January 1, 2000, and December 31, 2014, were included. Data of 89 CDKN2A-mut patients were extracted from the database of the Netherlands Foundation for Detection of Hereditary Tumors. A population-based cohort of 56,929 patients with sporadic melanoma was extracted from PALGA (the Dutch Nationwide Network and Registry of Histopathology and Cytopathology) and the Netherlands Cancer Registry. Ethical approval was granted by the ethical review boards of PALGA and Leiden University Medical Center. Cox proportional hazards regression analyses were performed. See the Supplementary Text (available via Mendeley at https://doi.org/10.17632/h4m4zwdysx.1) for all statistical analyses. Funding sources: None.